Feldetrex

**Feldetrex** is an unapproved proprietary fixed-dose drug candidate developed by Premier Biomedical for symptom management in fibromyalgia, neuropathic pain, muscular pain, multiple sclerosis, traumatic brain injury, and chemical addiction. Public company disclosures characterize it as a patented combination of FDA-approved compounds; SEC correspondence specifically describes it as naltrexone with added vitamins, while the complete composition, doses, formulation, and specific vitamin components have not been publicly disclosed. A planned double-blind study at William Beaumont Army Medical Center proposed comparisons of placebo, pregabalin, Feldetrex, and a pregabalin-Feldetrex blend, but no completed registered trial or regulatory approval was identified. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1515740/000114420411056360/filename21.htm))

Brand names

Feldetrex